Semiconductor automation was one of two growth platforms in Brooks Automation’s strategy presented at its May 2018 Investor Day. The other was life sciences sample management. The company’s case for developing both businesses rested on distinct but related customer needs: semiconductor manufacturers sought equipment capabilities to address increasingly complex processes, while researchers and healthcare organizations needed ways to manage growing collections of biological samples.
Brooks described a strategy built around extending positions in core markets, investing in growth opportunities, improving margins and deploying capital with attention to returns. Its 2021 goals were forward-looking targets presented in 2018—not statements of subsequently achieved results—and included revenue of $1.05 billion to $1.18 billion and operating margins of approximately 21%.
Two businesses with different automation demands
The semiconductor business supplied technologies for equipment manufacturers and device makers. Its portfolio included vacuum automation, cryogenic pumping and cooling, advanced packaging, wafer transport, contamination control and service. These capabilities support demanding equipment and process environments, where wafer handling, vacuum transport and particle control are important considerations.
Brooks identified wafer-level packaging, deposition and etch, and contamination control as growth areas within the semiconductor equipment market. It argued that technology developments—including more complex wafer structures and advanced packaging applications—were increasing demand for capabilities in these segments. Design wins were presented as an indicator of future opportunity, although the presentation noted that wins in 2017 were expected to contribute to growth in 2019 and beyond rather than immediately translating into revenue.
The life sciences business addressed a different operational challenge: keeping samples organized, accessible and appropriately managed across research and clinical workflows. Its offerings spanned automated storage, consumables and instruments, scientific services, logistics and informatics. The goal was to support more of the sample journey, from collection and transport through processing, storage, retrieval and data management.
Semiconductor automation: focus on process challenges
Brooks’ semiconductor strategy emphasized solving customer technical challenges and building on established engineering and service capabilities. In its 2018 presentation, the company described its position across vacuum automation, advanced packaging and contamination control as a way to participate in areas it viewed as growing faster than the broader wafer fabrication equipment market.
Examples of the challenges and applications identified included:
- Vacuum automation: transporting wafers within equipment, including applications associated with smaller process dimensions and more demanding process requirements.
- Advanced packaging: handling complex wafers and supporting applications such as plasma dicing and bonding.
- Contamination control: managing the cleanliness and integrity of carriers and reticles, including requirements associated with EUV lithography.
The company also highlighted local engineering, manufacturing and service in Korea as part of its approach to supporting original equipment manufacturers. More broadly, it pointed to a combination of new product development, market-share gains, customer design wins and a broader customer base as contributors to growth. For equipment builders and integrators, the strategic implication is that component and subsystem suppliers compete not only on individual hardware, but also on how their capabilities address process-specific requirements and customer support needs.
Life sciences sample management as an integrated workflow
In life sciences, Brooks presented sample management as a connected service and infrastructure opportunity rather than a storage-only business. Its portfolio included automated cold storage, sample media, instruments, scientific services and informatics. Integrating those elements could support customer workflows that involve preparing, transporting, storing and retrieving samples, while making related information easier to manage.
The company cited trends including biologics, precision and regenerative medicine, genomics, outsourcing and digital technology as drivers of demand. These developments increase the importance of sample quality, annotation, storage options and access to supporting services. Brooks’ strategy was to expand within existing customer relationships, add capabilities across the sample workflow and enter additional markets and geographies.
Recurring revenue was another important part of the business model described in the presentation. Storage, services and consumables could create ongoing customer relationships beyond an initial equipment sale. Brooks also described acquisitions as a means of expanding its capabilities and customer offerings. The practical point for technical decision-makers is that sample infrastructure decisions can involve more than selecting a storage system: workflow integration, informatics, service and consumables may also affect how a solution fits an organization’s operations.
Growth strategy tied to execution and returns
Across both platforms, Brooks outlined four strategic priorities: extend leadership in core markets, grow life sciences through internal investment and acquisitions, expand margins, and use capital in a balanced and disciplined way. The company also reported consolidating operations and completing acquisitions during the years leading up to Investor Day. These actions were presented as part of a broader transformation toward higher-growth markets and improved profitability.
The financial outlook reflected the company’s expectations at the time. Brooks projected that semiconductor revenue would reach $720 million to $850 million by 2021, while life sciences revenue was targeted at $330 million. It also projected consolidated revenue of $1.05 billion to $1.18 billion and non-GAAP operating income of $215 million to $255 million. The presentation specified that its non-GAAP measures should be considered alongside the corresponding GAAP measures, and that projections excluded certain items such as amortization, restructuring expenses and other special charges.
What the strategy means for automation decision-makers
Brooks’ 2018 plan illustrates how an automation supplier can pursue growth across markets with different technical requirements. In semiconductor manufacturing, the focus was on equipment capabilities aligned with process complexity, wafer handling and contamination control. In life sciences, the opportunity was to connect storage automation with services, consumables and information management across sample workflows.
For engineers, integrators and operations leaders, the broader lesson is to assess suppliers in the context of the problem being solved: process compatibility and service support for semiconductor equipment, or workflow coverage and sample-management needs in life sciences. Brooks framed its two-platform strategy around these customer requirements, while its 2021 figures remained targets made in 2018 rather than guaranteed outcomes.